GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SMS Lifesciences India Ltd (BOM:540679) » Definitions » Debt-to-EBITDA

SMS Lifesciences India (BOM:540679) Debt-to-EBITDA : 1.84 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is SMS Lifesciences India Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

SMS Lifesciences India's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹652 Mil. SMS Lifesciences India's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹355 Mil. SMS Lifesciences India's annualized EBITDA for the quarter that ended in Mar. 2024 was ₹549 Mil. SMS Lifesciences India's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 1.84.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for SMS Lifesciences India's Debt-to-EBITDA or its related term are showing as below:

BOM:540679' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -18652.26   Med: 1.8   Max: 2.94
Current: 2.88

During the past 9 years, the highest Debt-to-EBITDA Ratio of SMS Lifesciences India was 2.94. The lowest was -18652.26. And the median was 1.80.

BOM:540679's Debt-to-EBITDA is ranked worse than
67.04% of 270 companies
in the Biotechnology industry
Industry Median: 1.31 vs BOM:540679: 2.88

SMS Lifesciences India Debt-to-EBITDA Historical Data

The historical data trend for SMS Lifesciences India's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SMS Lifesciences India Debt-to-EBITDA Chart

SMS Lifesciences India Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only 2.39 2.05 1.64 2.94 2.88

SMS Lifesciences India Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.55 - 2.90 - 1.84

Competitive Comparison of SMS Lifesciences India's Debt-to-EBITDA

For the Biotechnology subindustry, SMS Lifesciences India's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SMS Lifesciences India's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SMS Lifesciences India's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where SMS Lifesciences India's Debt-to-EBITDA falls into.



SMS Lifesciences India Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

SMS Lifesciences India's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(651.849 + 355.389) / 349.41
=2.88

SMS Lifesciences India's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(651.849 + 355.389) / 548.848
=1.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


SMS Lifesciences India  (BOM:540679) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


SMS Lifesciences India Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of SMS Lifesciences India's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


SMS Lifesciences India (BOM:540679) Business Description

Traded in Other Exchanges
Address
Road Number 71, Plot Number 19 - III, Opposite Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad, TG, IND, 500096
SMS Lifesciences India Ltd is engaged in the Business of manufacturing of Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, and Erectile Dysfunction.

SMS Lifesciences India (BOM:540679) Headlines

No Headlines